Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 21321093)

1.

A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy.

Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS.

J Mol Endocrinol. 2011 Apr 12;46(3):155-63. doi: 10.1530/JME-11-0006. Print 2011 Jun.

2.
3.

A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.

Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS.

J Clin Endocrinol Metab. 2012 May;97(5):1681-7. doi: 10.1210/jc.2011-2890. Epub 2012 Mar 7.

4.

A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.

Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengorn MC, Bahn RS.

J Clin Endocrinol Metab. 2013 May;98(5):2153-9. doi: 10.1210/jc.2013-1149. Epub 2013 Mar 12.

5.

Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.

van Zeijl CJ, Fliers E, van Koppen CJ, Surovtseva OV, de Gooyer ME, Mourits MP, Wiersinga WM, Miltenburg AM, Boelen A.

Thyroid. 2010 May;20(5):535-44. doi: 10.1089/thy.2009.0447.

PMID:
20384487
6.

Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy.

Zhao P, Deng Y, Gu P, Wang Y, Zhou H, Hu Y, Chen P, Fan X.

Exp Eye Res. 2013 Feb;107:65-73. doi: 10.1016/j.exer.2012.11.014. Epub 2012 Dec 5.

PMID:
23219871
7.

Biological effects of thyrotropin receptor activation on human orbital preadipocytes.

Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, Ludgate M.

Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5197-203.

9.

PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.

van Steensel L, Hooijkaas H, Paridaens D, van den Bosch WA, Kuijpers RW, Drexhage HA, van Hagen PM, Dik WA.

J Clin Endocrinol Metab. 2012 Jun;97(6):E944-53. doi: 10.1210/jc.2012-1020. Epub 2012 Mar 21.

PMID:
22438231
10.

Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist.

van Zeijl CJ, van Koppen CJ, Surovtseva OV, de Gooyer ME, Plate R, Conti P, Karstens WJ, Timmers M, Saeed P, Wiersinga WM, Miltenburg AM, Fliers E, Boelen A.

J Clin Endocrinol Metab. 2012 May;97(5):E781-5. doi: 10.1210/jc.2011-2931. Epub 2012 Mar 14.

PMID:
22419705
11.

The effects of nonionic polymers on thyroid stimulation and TSH receptor binding by the human monoclonal TSH receptor autoantibody M22.

Ochi Y, Hamazu M, Kajita Y, Hachiya T, Miyata T, Barrett C, Smith BR.

Thyroid. 2009 Jan;19(1):47-52. doi: 10.1089/thy.2007.0351.

PMID:
18976151
12.

A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts.

Neumann S, Pope A, Geras-Raaka E, Raaka BM, Bahn RS, Gershengorn MC.

Thyroid. 2012 Aug;22(8):839-43. doi: 10.1089/thy.2011.0520. Epub 2012 Jul 11.

13.

Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy.

Jyonouchi SC, Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS.

Thyroid. 2001 Oct;11(10):929-34.

PMID:
11716039
14.

Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor.

Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder AE, Jyonouchi SC, Bahn RS.

J Clin Endocrinol Metab. 1999 Jul;84(7):2557-62.

PMID:
10404836
15.

Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy.

Pasquali D, Pierantoni GM, Fusco A, Staibano S, Colantuoni V, De Bellis A, Bellastella A, Sinisi AA.

J Mol Endocrinol. 2004 Aug;33(1):133-43.

16.

Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy.

Kumar S, Coenen MJ, Scherer PE, Bahn RS.

J Clin Endocrinol Metab. 2004 Feb;89(2):930-5.

17.
18.

Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy.

Zhang L, Grennan-Jones F, Lane C, Rees DA, Dayan CM, Ludgate M.

J Clin Endocrinol Metab. 2012 Feb;97(2):653-62. doi: 10.1210/jc.2011-1299. Epub 2011 Dec 7.

PMID:
22162480
19.

Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy.

Zhang L, Grennan-Jones F, Draman MS, Lane C, Morris D, Dayan CM, Tee AR, Ludgate M.

J Clin Endocrinol Metab. 2014 Jul;99(7):E1183-90. doi: 10.1210/jc.2013-4182. Epub 2014 Apr 23.

PMID:
24758182
20.

Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.

Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC.

J Clin Endocrinol Metab. 2015 Mar;100(3):1071-7. doi: 10.1210/jc.2014-3566. Epub 2014 Dec 8.

PMID:
25485727
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk